BACKGROUND: Long-term local control in @entity463 is rarely achieved and nearly all @entity1 relapse. In this study we evaluated the clinical effect of different treatment approaches in recurrent @entity1 . METHODS: Forty-three @entity1 , with median age of 51  years were evaluated for salvage treatment: re-resection and/or re-irradiation plus chemotherapy or chemotherapy alone. Response was recorded using the Response Assessment in Neuro-Oncology criteria. Hematologic and non-hematologic @entity137 were graded according to Common Terminology Criteria for Adverse Events 4.0. Twenty-one @entity1 underwent chemotherapy combined with local treatment, surgery and/or radiation therapy, and 22 underwent chemotherapy only. RESULTS: The median follow up was 7  months (range 3-28 months). The 1 and 2-years Progression Free Survival was 65 and 10  % for combined treatment and 22 and 0  % for chemotherapy alone (p   <   0.01). The 1 and 2-years overall survival was 69 and 29  % for combined and 26 and 0  % for chemotherapy alone (p   <   0.01). No @entity137 greater than grade 2 was recorded. CONCLUSION: These data showed that in @entity463 recurrence the combination of several approaches in a limited group of @entity1 is more effective than a single treatment alone. This stress the importance of multimodality treatment whenever clinically feasible.

Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma', 'Glioblastoma']
@entity463 :: (MESH:D005909,Disease) :: ['glioblastoma']
